Stem cells have the potential to repair damaged tissues and replace cells in the human body. They are being extensively researched upon for their potential to treat conditions such as cancer, diabetes, cardiac infarction, neurological disorders and many more. Regenerative medicine is emerging as one of the most promising applications of stem cell research. Technological advancements are helping scientists grow stem cells in the laboratory and specialize them into cell types that can repair failing organs or tissues. The global stem cells market is estimated to be valued at US$ 12.9 Bn in 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: Increased R&D funding and investments in regenerative medicine offer a huge market opportunity for stem cell companies. Governments as well as private organizations are supporting stem cell research through funding and initiatives as it holds potential to revolutionize treatment for many incurable diseases. For instance, according to the Coalition for Regenerative Medicine, over $2 billion in private investment was poured into regenerative medicine start-ups in 2019 alone. With more clinical trials demonstrating feasibility and safety of various stem cell therapies, their commercialization and adoption could increase exponentially over the coming years. This is expected to boost the growth of the stem cells market during the forecast period. Porter's Analysis Threat of new entrants: Low barriers to entry due to easy availability of technology and services. However, established players have significant resources and reputation. Bargaining power of buyers: Buyers have moderate to high bargaining power due to availability of substitutes and focus on cost reduction. Bargaining power of suppliers: Suppliers of raw materials and services have low to moderate bargaining power due to availability of substitutes. Threat of new substitutes: Threat of substitutes is moderate as other regenerative medicine therapies can be used instead of stem cells. Competitive rivalry: Intense due to presence of global established players and developing new application areas. SWOT Analysis Strengths: Promising therapeutic applications, ongoing clinical trials, government support for research. Weaknesses: High costs, ethical issues, complex manufacturing process. Opportunities: Untapped emerging markets, new application areas like cancer, diabetes, neurological disorders. Threats: Stringent regulations, reimbursement challenges, intellectual property issues. Key Takeaways The global stem cells market is expected to witness high growth over the forecast period. Global Stem Cells Market Size is estimated to be valued at US$ 12.9 Bn in 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 to 2030. North America currently dominates the market due to presence of major market players, ongoing clinical trials and government support. However, Asia Pacific is expected to grow at the fastest pace during the forecast period owing to increasing investment in stem cell research, rising geriatric population, and growing healthcare expenditure. Key players operating in the stem cells market are Abzena Ltd., Clarivate, Immunetrics Inc., GNS Healthcare, Dassault Systemes, Evotec, Novadiscovery, Insilico Medicine Inc., and InSilicoTrials Technologies, among others. Some of the major players are focusing on expanding their product portfolio through acquisitions and collaborations with research institutes to develop advanced therapies and treatments for various diseases. Get More Insights on this Topic- https://www.marketwebjournal.com/stem-cells-market-forecast-analysis-and-trends/
0 Comments
Plasmid DNA Manufacturing Market Set to Witness High Growth Due to Rising Gene Therapy Demand1/3/2024 Plasmid DNA is circular double-stranded DNA molecules that can replicate independently of the chromosomal DNA inside bacterial cells or in vitro. Plasmid DNA is widely used in genetic engineering, recombinant protein expression, gene therapy and DNA vaccination development. In genetic engineering, plasmids are commonly used as cloning vectors to introduce new DNA segments into host organisms. They also play a vital role in recombinant DNA technology by acting as vectors to deliver therapeutic genes into target cells for gene therapy. Plasmid DNA finds major applications in development of gene therapeutics for treating cancer, infectious diseases, genetic disorders and more. The global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 901.2 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: The Plasmid DNA Manufacturing Market is witnessing high growth owing to rising demand for gene and cell therapies across the globe. Gene therapy involves use of plasmid DNA to introduce genetic material into patient's cells and tissues to treat diseases. Growing pipeline of gene therapy candidates and approval of novel gene therapies is expected to drive the demand for plasmid DNA. For instance, approval of chimeric antigen receptor T cell (CAR-T) therapies like Kymriah and Yescarta for treatment of cancers has fuelled plasmid DNA demand. Additionally, growing R&D investments by pharmaceutical and biotech companies into vector development is also spurring market growth. While plasmid DNA plays a crucial role, manufacturing remains a complex process requiring high quality standards. Key players are focusing on developing novel production technologies to address various challenges in plasmid DNA manufacturing like scale-up, contamination control, purification and more. This is expected to boost overall plasmid DNA supply to cater growing gene therapy clinical trials and commercialization in the forecast period. SWOT Analysis Strength: The Plasmid DNA Manufacturing market has strong growth potential due to the rising adoption of cell and gene therapies for cancer treatment. Growing R&D investments by pharmaceutical companies and increasing outsourcing of plasmid DNA production are further propelling market growth. Additionally, advancements in plasmid manufacturing technologies such as high-yield plasmid purification and scalable transfection are driving efficiencies. Weakness: Rigorous regulatory compliance and high capital investment requirements pose challenges for market players. Limited expertise and high costs associated with plasmid DNA production also constrain market growth to some extent. Opportunity: Increasing pipeline of gene therapy candidates and growing clinical trials for genetic disorders present lucrative opportunities. Further, the market sees opportunities from the rising demand for plasmid DNA in viral vector production and vaccine manufacturing. Growing pharmaceutical outsourcing in Asia also provides opportunities for market expansion. Threats: Complexities associated with plasmid DNA production processes increase the risk of manufacturing delays and failures. Intellectual property disputes among market players also threaten the market growth. Rising competition from new entrants poses pricing pressures. Key Takeaways The global Plasmid DNA Manufacturing market is expected to witness high growth. Global Plasmid DNA Manufacturing Market Size is estimated to be valued at US$ 901.2 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030. Regional analysis related content comprises the North American region currently dominates the market and is expected to maintain its leadover the forecast period. Growing R&D expenditure and presence of key players drive the North American market. Key players operating in the Plasmid DNA Manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga. Get More Insights on this Topic- https://www.dailyprbulletin.com/plasmid-dna-manufacturing-market-value-analysis-and-trends/ The global Oligonucleotide Synthesis Market is estimated to be valued at US$ 2,874.1 Mn in 2020 and is expected to exhibit a CAGR of 11.3% over the forecast period 2020-2027, as highlighted in a new report published by Coherent Market Insights. A) Market Overview: Oligonucleotide synthesis is the chemical synthesis of relatively short fragments of nucleic acids, typically DNA or RNA, with defined chemical structures. These synthetic oligonucleotides have various applications in the fields of genetic analysis, molecular biology research, pharmaceutical development, and diagnostics. They are widely used in techniques such as PCR, DNA sequencing, gene synthesis, and gene editing. Oligonucleotide synthesis provides several advantages, including high efficiency, cost-effectiveness, and specificity in nucleic acid research and applications. B) Market Key Trends: One key trend influencing the global oligonucleotide synthesis market is the advancements in technology. The field of oligonucleotide synthesis has witnessed rapid advancements in recent years. Automation and higher-throughput systems have enabled the synthesis of larger quantities of oligonucleotides at a faster pace. Additionally, new technologies such as microarray-based synthesis and next-generation sequencing have revolutionized the field by enabling high-throughput synthesis and analysis of oligonucleotides. These technological advancements have significantly contributed to the growth and expansion of the oligonucleotide synthesis market. For example, Twist Bioscience, one of the key players in the market, utilizes silicon-based DNA synthesis technology for high-throughput production of oligonucleotides. This technology enables the parallel synthesis of thousands of oligonucleotides in a cost-effective and efficient manner. C) PEST Analysis: - Political: Oligonucleotide synthesis is influenced by government regulations related to the use and handling of nucleic acids, as well as intellectual property rights and patent laws. - Economic: The increasing demand for oligonucleotide synthesis products and services in various fields such as pharmaceuticals, research, and diagnostics is driving the growth of the market. Economic factors such as investments in research and development and healthcare expenditure also impact the market. - Social: The growing awareness and understanding of genetic diseases, personalized medicine, and precision agriculture are driving the demand for oligonucleotide synthesis products. The increasing adoption of genetic testing and gene-based therapies is also contributing to market growth. - Technological: Technological advancements in the field of oligonucleotide synthesis, such as automation, high-throughput systems, and next-generation sequencing, are driving market growth. Oligonucleotide synthesis technologies are evolving to meet the increasing demand for higher quality, purity, and scale. D) Key Takeaways: - The global Oligonucleotide Synthesis Market is expected to witness high growth, exhibiting a CAGR of 11.3% over the forecast period. This growth can be attributed to increasing applications of oligonucleotides in genetic analysis, molecular biology research, pharmaceutical development, and diagnostics. Additionally, advancements in technology, such as automation and high-throughput systems, are driving market growth. - North America is the fastest-growing and dominating region in the global oligonucleotide synthesis market. This can be attributed to factors such as the presence of major players in the region, significant investments in research and development, and the high adoption rate of advanced technologies. - Key players operating in the global oligonucleotide synthesis market include Thermo Fisher Scientific, Sigma-Aldrich Corporation, GE Healthcare, Integrated DNA Technologies, Inc., TriLink Biotechnologies’, Inc, BioAutomation Corporation, Twist Bioscience, Shanghai SynTheAll Pharmaceutical Co., CUSABIO Technology LLC, Synbio Technologies, GENEWIZ, Eurofins Scientific, Agilent Technologies, Kaneka Eurogentec S.A., and LGC, Biosearch Technologies. These players are focused on strategic initiatives such as collaborations, acquisitions, and product launches to strengthen their market position and expand their product offerings. In conclusion, the global oligonucleotide synthesis market is expected to witness significant growth due to technological advancements, increasing applications in various fields, and the presence of key players driving innovation in the market. As the demand for genetic analysis and molecular biology research continues to grow, the market is poised for further expansion in the coming years. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
January 2024
Categories
All
|